がん幹細胞の市場シェア、規模、動向分析レポート：作用機序別、がん形態別、地域別、セグメント予測、2023年～2030年

がん幹細胞市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のがん幹細胞市場規模は2030年までに31億米ドルに達し、予測期間中にCAGR 12.09％で拡大する見込みです。

幹細胞を用いたがん治療は規制や倫理的な課題に直面しているが、市場は世界的に拡大しています。幹細胞に対する認識が高まるにつれ、幹細胞を用いた効果的かつ新規の治療法開発のための研究開発も着実に成長しています。

さらに、がん幹細胞（CSC）に関する調査研究の発表数も増加の一途をたどっています。これらの研究は、ヘルスケアの専門家がCSCsの生物学とそのシグナル伝達経路に関する洞察を得るのに役立っています。このことは、同市場に大きな成長の展望をもたらすと期待されています。

さらに、実験的アプローチ、特にin vitroアッセイシステムの改善により、科学者は腫瘍内の異なる細胞タイプとその微小環境との関係を確立できるようになっています。これにより、腫瘍の成長を抑制し、臨床転帰を改善するために、CSCsとそれに関連する主要経路に対する幅広い治療ポートフォリオが開発されるようになっています。

がん幹細胞市場レポート・ハイライト

• 栄養補助食品は2022年の売上高シェアで60%を占め、市場を独占しています。これは、栄養補助食品における消費者の嗜好が、化学ベースの成分からオーガニックやハーブの成分へと変化しているためです。
• eコマースの普及とオンラインで製品を提供するプレイヤーの増加により、オンラインストアが予測期間中に最も急成長する流通チャネル・セグメントになると予想されます。
• 北米はカンナビジオール消費者向け健康製品のがん幹細胞市場を独占し、2022年の売上高シェアは約70％でした。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 がん幹細胞市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 普及と成長の見通しマッピング
• 業界のバリューチェーン分析
  • 償還の枠組み
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• がん幹細胞市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 がん幹細胞：作用推定・動向分析

• がん幹細胞市場：重要なポイント
• がん幹細胞市場：動向と市場シェア分析、2022年および2030年
• 標的化されたがん性幹細胞（CSC）
  • 対象となるがん性幹細胞市場推計・予測、2018年から2030年まで
• 幹細胞ベースのがん治療
  • 幹細胞ベースのがん治療市場推計・予測、2018年から2030年まで

第5章 がん幹細胞：がんの形態の推定・動向分析

• がん幹細胞市場：重要なポイント
• がん幹細胞市場：動向と市場シェア分析、2022年および2030年
• 乳がん
• 血液がん
• 肺がん
• 脳腫瘍
• 結腸直腸がん
• 膵臓がん
• 膀胱がん
• 肝臓がん
• その他のがん

第6章 がん幹細胞市場：地域推定・動向分析

• 地域別の見通し
• 地域別がん幹細胞市場：主要なマーケットプレース要点
• 北米
  • 市場推計・予測、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • スウェーデン
  • ノルウェー
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類
  • Thermo Fisher Scientific, Inc.
  • AbbVie, Inc.
  • Merck KGaA
  • Bionomics
  • Lonza
  • Stemline Therapeutics, Inc.
  • Miltenyi Biotec
  • PromoCell GmbH
  • MacroGenics, Inc.
  • FUJIFILM Irvine Scientific
  • STEMCELL Technologies.
  • Sino Biological, Inc.
  • Lineage Cell Therapeutics, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 North America cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 3 North America cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 4 North America cancer stem cells market, by region, 2018 - 2030 (USD Million)
• Table 5 U.S. cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 6 U.S. cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 7 Canada cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 8 Canada cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 9 Europe cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 10 Europe cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 11 Europe cancer stem cells market, by region, 2018 - 2030 (USD Million)
• Table 12 UK cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 13 UK cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 14 Germany cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 15 Germany cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 16 France cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 17 France cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 18 Italy cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 19 Italy cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 20 Spain cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 21 Spain cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 22 Sweden cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 23 Sweden cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 24 Norway cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 25 Norway cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 26 Denmark cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 27 Denmark cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific cancer stem cells market, by region, 2018 - 2030 (USD Million)
• Table 31 Japan cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 32 Japan cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 33 China cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 34 China cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 35 India cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 36 India cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 37 Australia cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 38 Australia cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 39 Thailand cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 40 Thailand cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 41 South Korea cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 42 South Korea cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 43 Latin America cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 44 Latin America cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 45 Latin America cancer stem cells market, by region, 2018 - 2030 (USD Million)
• Table 46 Brazil cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 47 Brazil cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 48 Mexico cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 49 Mexico cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 50 Argentina cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 51 Argentina cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 52 Middle East and Africa cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 53 Middle East and Africa cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 54 Middle East and Africa cancer stem cells market, by region, 2018 - 2030 (USD Million)
• Table 55 Saudi Arabia cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 56 Saudi Arabia cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 57 South Africa cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 58 South Africa cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 59 UAE cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 60 UAE cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)
• Table 61 Kuwait cancer stem cells market, by mode of action, 2018 - 2030 (USD Million)
• Table 62 Kuwait cancer stem cells market, by cancer forms, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Cancer stem cells: Market outlook
• Fig. 9 Cancer stem cells: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Cancer stem cells market driver impact
• Fig. 15 Cancer stem cells market restraint impact
• Fig. 16 Cancer stem cells strategic initiatives analysis
• Fig. 17 Cancer stem cells market: Mode of action movement analysis
• Fig. 18 Cancer stem cells market: Mode of action outlook and key takeaways
• Fig. 19 Targeted cancerous stem cells market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 By anti-cancer stem cell therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Pathway inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 WNT signaling pathway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Hedgehog signaling pathway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Notch signaling pathway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Surface marker-based market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Immuno-evasion & targeting tumor microenvironment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Nanoparticle-based therapies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 By product market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Cell culturing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Cell separation market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Cell analysis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Molecular analysis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Stem cell-based cancer therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Autologous stem cell transplant market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Allogeneic stem cell transplant market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Cancer stem cells market: Cancer forms movement analysis
• Fig. 40 Cancer stem cells market: Cancer forms outlook and key takeaways
• Fig. 41 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Brain cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Colorectal cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Pancreatic cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Bladder cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Other cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Global cancer stem cells market: Regional movement analysis
• Fig. 51 Global cancer stem cells market: Regional outlook and key takeaways
• Fig. 52 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Cancer Stem Cells Market Growth & Trends:

The global cancer stem cells market size is expected to reach USD 3.1 billion by 2030, according to a new report by Grand View Research, Inc.., expanding at a CAGR of 12.09% during the forecast period. Although stem cell-based cancer treatment is facing regulatory and ethical challenges, the market is growing worldwide. With increasing awareness about these cells, there is steady growth in the R&D for the development of effective and novel treatment methods based on stem cells.

Furthermore, continuous rise has been observed in the number of research studies on cancer stem cells (CSCs) being published. These studies have helped healthcare professionals gain insights into CSCs biology and their signaling pathways. This is expected to create tremendous growth prospects for the market.

Furthermore, improvements in experimental approaches, in particular, in vitro assay systems have enabled scientists to establish relationship between different cell types in a tumor and their microenvironment. This has led to development of a broad therapeutic portfolio for CSCs and their associated key pathways for restricting growth of the tumor and providing improved clinical outcome.

Cancer Stem Cells Market Report Highlights:

• Nutraceuticals dominated the market in 2022 with a revenue share of 60%, owing to the changing consumer preferences from chemical-based ingredients to organic and herbal ingredients in dietary supplements
• Online stores is anticipated to be the fastest-growing distribution channel segment over the forecast period, owing to the increase in penetration of e-commerce and the rising number of players offering their products online
• North America dominated the Cancer Stem Cells market for cannabidiol consumer health products, with a revenue share of around 70% in 2022.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Mode of action
  • 1.1.2. Cancer forms
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Mode of action
  • 2.2.2. Cancer forms
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Stem Cells Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
  • 3.4.1. Market Driver Analysis
  • 3.4.2. Market Restraint Analysis
• 3.5. Cancer Stem Cells Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic Landscape

Chapter 4. Cancer Stem Cells: Mode of Action Estimates & Trend Analysis

• 4.1. Cancer Stem Cells Market: Key Takeaways
• 4.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Targeted Cancerous Stem Cells (CSCs)
  • 4.3.1. Targeted cancerous stem cells market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1. By anti-cancer stem cell therapeutics
    • 4.3.1.1.1. By anti-cancer stem cell therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.1. Pathway inhibitors
    • 4.3.1.1.1.1.1. Pathway inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.1.1.1. WNT signaling pathway
    • 4.3.1.1.1.1.1.1.1. WNT signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.1.1.2. Hedgehog signaling pathway
    • 4.3.1.1.1.1.1.2.1. Hedgehog signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.1.1.3. Notch signaling pathway
    • 4.3.1.1.1.1.1.3.1. Notch signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.1.1.4. Others
    • 4.3.1.1.1.1.1.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.2. Surface marker-based
    • 4.3.1.1.1.2.1. Surface marker-based market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.3. Immuno-evasion & targeting tumor microenvironment
    • 4.3.1.1.1.3.1. Immuno-evasion & targeting tumor microenvironment market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.4. Nanoparticle-based therapies
    • 4.3.1.1.1.4.1. Nanoparticle-based therapies market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.1.1.5. Others
    • 4.3.1.1.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.2. By-products
    • 4.3.1.2.1. By products market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.2.1.1. Cell culturing
    • 4.3.1.2.1.1.1. Cell culturing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.2.1.2. Cell Separation
    • 4.3.1.2.1.2.1. Cell separation market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.2.1.3. Cell Analysis
    • 4.3.1.2.1.3.1. Cell analysis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.2.1.4. Molecular analysis
    • 4.3.1.2.1.4.1. Molecular analysis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.1.2.1.5. Others
    • 4.3.1.2.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Stem Cell-based Cancer Therapy
  • 4.4.1. Stem cell-based cancer therapy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.1. Autologous stem cell transplant
    • 4.4.1.1.1. Autologous stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.2. Allogeneic stem cell transplant
    • 4.4.1.2.1. Allogeneic stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cancer Stem Cells: Cancer Forms Estimates & Trend Analysis

• 5.1. Cancer Stem Cells Market: Key Takeaways
• 5.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Breast Cancer
  • 5.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Blood Cancer
  • 5.4.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Lung Cancer
  • 5.5.1. Lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Brain Cancer
  • 5.6.1. Brain cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Colorectal Cancer
  • 5.7.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Pancreatic Cancer
  • 5.8.1. Pancreatic cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Bladder Cancer
  • 5.9.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. Liver Cancer
  • 5.10.1. Liver cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.11. Other Cancer
  • 5.11.1. Other cancer market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cancer Stem Cells Market: Regional Estimates & Trend Analysis

• 6.1. Regional Outlook
• 6.2. Cancer Stem Cells Market by Region: Key Marketplace Takeaway
• 6.3. North America
  • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.3. France
    • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.6. Sweden
    • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.7. Norway
    • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. China
    • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. India
    • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. MEA
  • 6.7.1. Saudi Arabia
    • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Market Participant Categorization
  • 7.2.1. Thermo Fisher Scientific, Inc.
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product Benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. AbbVie, Inc.
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Merck KGaA
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Bionomics
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Lonza
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Stemline Therapeutics, Inc.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Miltenyi Biotec
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. PromoCell GmbH
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. MacroGenics, Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. FUJIFILM Irvine Scientific
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. STEMCELL Technologies.
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Sino Biological, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. Lineage Cell Therapeutics, Inc.
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives